FutureChem Co

FutureChem Co Financial Leverage

The Financial Leverage (Equity Multiplier) of FutureChem Co (220100.KQ) as of Oct 21, 2026 is 1.36. In the previous year, Financial Leverage (Equity Multiplier) was 1.37 — a change of -0.35% (lower).

Financial Leverage

1.36

YoY

-0.35%

Last updated:

Financial Leverage (Equity Multiplier) of FutureChem Co is 2025 1.36 . Financial Leverage (Equity Multiplier) of FutureChem Co was 2024 1.37 . It decreases by -0.35% lower compared to the previous year.

The FutureChem Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
3.89 KRW
Jan 1, 2019
5.66 KRW
Jan 1, 2020
1.90 KRW
Jan 1, 2021
1.46 KRW
Jan 1, 2022
1.26 KRW
Jan 1, 2023
1.14 KRW
Jan 1, 2024
1.37 KRW
Jan 1, 2025
1.36 KRW
The FutureChem Co Financial Leverage history
YEARFinancial LeverageYoY
1.36-0.35%
1.37+19.82%
1.14-9.71%
1.26-13.55%
1.46-23.03%
1.90-66.42%
5.66+45.48%
3.89+194.08%
1.32+26.05%
1.05-133.70%
-3.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

FutureChem Co Stock analysis

What does FutureChem Co do? FutureChem Co., Ltd. generates revenue through the manufacture and distribution of radiopharmaceuticals, including diagnostic agents for lung cancer, Parkinson's disease, and Alzheimer's disease. The company produces medical automation modules such as cubes, disposable cassettes, reagent kits, radio-caps, and kryptofix kits, alongside PET and SPECT precursors for radiopharmaceuticals. These products are sold to healthcare providers, diagnostic centers, and medical facilities requiring specialized radiopharmaceutical solutions. The firm also develops metal chelating agents and fluorescence probes for medical applications. The primary buyers of FutureChem's products include hospitals, clinics, and research institutions focused on cancer diagnostics and neurological conditions. Medical automation modules and disposable goods are utilized in diagnostic procedures, while PET and SPECT precursors support imaging technologies. Metal chelating agents and fluorescence probes are integrated into medical testing and imaging processes. FutureChem's revenue streams are driven by the demand for advanced diagnostic tools in oncology and neurology. The company's portfolio targets healthcare segments requiring early detection of diseases, with products designed for both diagnostic imaging and laboratory testing. Sales are concentrated in medical facilities that prioritize precision diagnostics and specialized treatment planning. FutureChem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FutureChem Co stock

Financial Leverage (Equity Multiplier) of FutureChem Co is 1.36 in 2025.

Financial Leverage (Equity Multiplier) of FutureChem Co changed from 1.37 to 1.36, representing a -0.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) FutureChem Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s FutureChem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — FutureChem Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — FutureChem Co